Yah Ru Juang

Yah Ru Juang

Auto-generated profile, based on publicly available information

Yah Ru Juang

Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
YJYah Ru Juang
Yah Ru Juang
MHMeijing Hu
Meijing Hu
MHMiao Hui
Miao Hui
ASAdeline Seow
Adeline Seow
ITIain Bee Huat Tan
Iain Bee Huat Tan
Wei Jie SeowWei Jie Seow
Wei Jie Seow
Lung cancer remains a leading cause of cancer-related deaths globally. Although evidence indicates rising early-onset cases and increasing incidence among females and never-smokers in Asia, these trends remain underexplored in Singapore. This study comprehensively examined historical incidence trends by age, sex, smoking status, and stage to inform targeted prevention and management strategies. We analyzed lung cancer cases from administrative health records in Singapore (1968–2021) to calculate age-standardized and age-specific incidence by age (30–49 years, 50–64 years, ≥65 years), sex (male, female), smoking status (ever-, never-smokers), and stage (I–IV). Joinpoint regression identified significant trend changes, reporting annual percent change (APC), average annual percent change (AAPC), and 95% confidence intervals (CIs). AAPCs were evaluated for the full study period and the most recent five years, with Benjamini-Hochberg adjustment for multiple comparisons. From 1968 to 2021, 53,308 lung cancer cases were recorded in Singapore, predominantly in males (67.7%) and Chinese (87.8%), with 81.6% at advanced stages (III–IV). Incidence rose significantly only in females aged 30–49 years (AAPC = 0.79%, 95% CI: 0.41–1.18) and declined in all male age groups, especially 50–64 years (AAPC = −1.34%, 95% CI: −1.53 to −1.12). Stage I diagnoses increased significantly in both sexes (females: AAPC = 7.19%, 95% CI: 5.24–9.22; males: AAPC = 3.79%, 95% CI: 1.94–5.46) and incidence among never-smokers rose significantly, particularly among females (AAPC = 4.06%, 95% CI: 2.99–5.11). The narrowing male-female gap, rising early-onset cases among females, and increasing incidence in female never-smokers, particularly those ≥65 years, highlight a shifting lung cancer burden in Singapore. Despite improvements in early-stage detection, most cases remained advanced, emphasizing the need to strengthen lung cancer management and screening strategies in Singapore. This work is supported by the National Medical Research Council (Singapore) Health Promotion, Preventive Health, Population Health and Health Services Research (HPHSR) Clinician Scientist Award (HCSAINV24jul-0002).

1 September 2026 in Health Affairs Scholar
Verified
Journal Article
Open access
APAdena Li Tyin Peh
Adena Li Tyin Peh
Yot TeerawattananonYot Teerawattananon
Yot Teerawattananon
JYJeanette Xue Yan Yuen
Jeanette Xue Yan Yuen
NCNordin Charafi
Nordin Charafi
DTDicky Levenus Tahapary
Dicky Levenus Tahapary
Wenjia ChenWenjia Chen
Wenjia Chen
Background: Precision medicine (PM) adoption is accelerating across Asia, but implementation remains uneven due to differences in financing, infrastructure, governance, and health-system readiness. Objectives: To examine how six Asian countries (Singapore, South Korea, China, Malaysia, Thailand, and Indonesia) adopt, finance, and integrate PM technologies, and identify common implementation patterns and challenges. Methods: A landscape review of peer-reviewed literature, government publications, and HTA reports (2010-2026) was conducted, supplemented by stakeholder consultations. PM applications were grouped into public health screening (hereditary breast and ovarian cancer [HBOC] and familial hypercholesterolemia [FH] cascade testing), next-generation sequencing (NGS) applications (rare diseases, oncology, pharmacogenomics), and AI-enabled PM. Evidence was synthesized across access, awareness, reimbursement, and implementation. Results: Public health genomic screening demonstrated the highest implementation readiness, followed by precision oncology, while rare disease diagnostics remained infrastructure-dependent and pharmacogenomics and AI-enabled PM platforms were at earlier stages. Four readiness profiles emerged: highly aligned systems; reimbursement-constrained systems with strong governance and infrastructure; systems strengthening governance, public financing and infrastructure; and strategy-led systems expanding implementation through pilot programs and referral centers. Conclusions: PM implementation across Asia remains heterogeneous. The identified readiness profiles highlight governance, financing, and infrastructure priorities for sustainable and equitable PM diffusion.

2 May 2026 in Clinical Lung Cancer
Verified
Journal Article
Closed access
YJYah Ru Juang
Yah Ru Juang
WCWenjia Chen
Wenjia Chen
ANAlvin Jing Hui Ng
Alvin Jing Hui Ng
XSXueling Sim
Xueling Sim
DLDarren Wan-Teck Lim
Darren Wan-Teck Lim
Wei Jie SeowWei Jie Seow
Wei Jie Seow

1 September 2026 in Pharmacoeconomics and Policy
Verified
Journal Article
Open access
DBDimple Butani
Dimple Butani
YJYah Ru Juang
Yah Ru Juang
LLLaura Huey Mien Lim
Laura Huey Mien Lim
Alec MortonAlec Morton
Alec Morton
Jingmei LiJingmei Li
Jingmei Li
Wenjia ChenWenjia Chen
Wenjia Chen